Skip to main content

Congenital Pseudarthrosis of Tibia

2
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novadip Biosciences
Novadip BiosciencesBelgium - Mont-Saint-Guibert
2 programs
1
1
NVD003Phase 31 trial
NVD-003, an autologous 3D scaffold free osteogenic graftPhase 11 trial
Active Trials
NCT05693558Unknown4Est. Jan 2026
NCT07112443Recruiting12Est. Jul 2027
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
kirschner wireN/A1 trial
llizarov external fixation deviceN/A1 trial
Active Trials
NCT03257826Unknown100Est. Dec 2022
NCT02640040Unknown100Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Novadip BiosciencesNVD003
Novadip BiosciencesNVD-003, an autologous 3D scaffold free osteogenic graft
UNION therapeuticsllizarov external fixation device
UNION therapeuticskirschner wire

Clinical Trials (4)

Total enrollment: 216 patients across 4 trials

NCT07112443Novadip BiosciencesNVD003

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Start: Sep 2025Est. completion: Jul 202712 patients
Phase 3Recruiting
NCT05693558Novadip BiosciencesNVD-003, an autologous 3D scaffold free osteogenic graft

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

Start: Nov 2022Est. completion: Jan 20264 patients
Phase 1Unknown
NCT02640040UNION therapeuticsllizarov external fixation device

The Effect of Combined Surgery in Management of Congenital Pseudarthrosis of Tibia

Start: Aug 2015Est. completion: Dec 2025100 patients
N/AUnknown
NCT03257826UNION therapeuticskirschner wire

The Effect of Percutaneous Kirschner Wire Technique in Management of CPT Under One Year Old

Start: Aug 2015Est. completion: Dec 2022100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 216 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.